[1] L. Z. Li, H. N. Xu, M. Ranji, S. Nioka, B. Chance, "Mitochondrial redox imaging for cancer diagnostic and therapeutic studies," JIOHS 2, 325-341 (2009).

[2] B. Quistorff, J. C. Haselgrove, B. Chance, "High spatial resolution readout of 3-D metabolic organ structure: An automated, low-temperature redox ratio-scanning instrument," Anal. Biochem. 148, 389-400 (1985).

[3] H. N. Xu, S. Nioka, J. D. Glickson, B. Chance, L. Z. Li, "Quantitative mitochondrial redox imaging of breast cancer metastatic potential," J. Biomed. Opt. 15, 036010 (2010).

[4] L. Z. Li, R. Zhou, H. N. Xu, L. Moon, T. Zhong, E. J. Kim, H. Qiao, R. Reddy, D. Leeper, B. Chance, J. D. Glickson, "Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential," Proc. Natl. Acad. Sci. USA 106, 6608-6613 (2009).

[5] H. N. Xu, S. Nioka, B. Chance, L. Z. Li, "Heterogeneity of mitochondrial redox state in premalignant pancreas in a PTEN null transgenic mouse model," Adv. Exp. Med. Biol. 701, 207-213, (2011).

[6] Z. Zhang, D. Blessington, H. Li, T. M. Busch, J. Glickson, Q. Luo, B. Chance, G. Zheng, "Redox ratio of mitochondria as an indicator for the response of photodynamic therapy," J. Biomed. Opt. 9, 772-778 (2004).

[7] H. Poptani, N. Bansal, W. T. Jenkins, D. Blessington, A. Mancuso, D. S. Nelson, M. Feldman, E. J. Delikatny, B. Chance, J. D. Glickson, "Cyclophosphamide treatment modifies tumor oxygenation and glycolytic rates of RIF-1 tumors: C-13 magnetic resonance spectroscopy, Eppendorf electrode, and redox scanning," Cancer Res. 63, 8813-8820 (2003).

[8] A. C. Society, Cancer Facts & Figures 2012, American Cancer Society, Atlanta (2012).

[9] R. I. Fisher, E. R. Gaynor, S. Dahlberg, M. M. Oken, T. M. Grogan, E. M. Mize, J. H. Glick, C. A. Coltman, T. P. Miller, "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma," N. Engl. J. Med. 328, 1002-1006 (1993).

[10] R. M. Mohammad, A. Al-Katib, A. Aboukameel, D. R. Doerge, F. Sarkar, O. Kucuk, "Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy," Mol. Cancer Therap. 2, 1361-1368 (2003).

[11] S.-C. Lee, M. Q. Huang, D. S. Nelson, S. Pickup, S. Wehrli, O. Adegbola, H. Poptani, E. J. Delikatny, J. D. Glickson, "In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft," NMR Biomed. 21, 723 (2008).

[12] H. N. Xu, B. Wu, S. Nioka, B. Chance, L. Z. Li, "Quantitative redox scanning of tissue samples using a calibration procedure," JIOHS 2, 375-385 (2009).

[13] S. Fulda, L. Galluzzi, G. Kroemer, "Targeting mitochondria for cancer therapy," Nat. Rev. Drug Discov. 9, 447-464 (2010).

[14] G. G. D'Souza, M. A. Wagle, V. Saxena, A. Shah, "Approaches for targeting mitochondria in cancer therapy," Biochim. Biophys. Acta 1807, 689-696 (2011).

[15] N. Andre, D. Braguer, G. Brasseur, A. Goncalves, D. Lemesle-Meunier, S. Guise, M. A. Jordan, C. Briand, "Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells," Cancer Res. 60, 5349-5353 (2000).

[16] A. V. Kuznetsov, R. Margreiter, A. Amberger, V. Saks, M. Grimm, "Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicininduced cell death," Biochim. Biophys. Acta. 1813, 1144-1152 (2011).

[17] S. Lobert, B. Vulevic, J. J. Correia, "Interaction of vinca alkaloids with tubulin: A comparison of vinblastine, vincristine, and vinorelbine," Biochemistry 35, 6806-6814 (1996).

[18] R. J. Owellen, C. A. Hartke, R. M. Dickerson, F. O. Hains, "Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class," Cancer Res. 36, 1499-1502 (1976).

[19] R. J. Owellen, A. H. Owens, Jr., D. W. Donigian, "The binding of vincristine, vinblastine and colchicine to tubulin," Biochem. Biophys. Res. Commun. 47, 685-691 (1972).

[20] M. Carre, N. Andre, G. Carles, H. Borghi, L. Brichese, C. Briand, D. Braguer, "Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel," J. Biol. Chem. 277, 33664-33669 (2002).

[21] M. Ranji, D. L. Jaggard, B. Chance, "Observation of mitochondrial morphology and biochemistry changes undergoing apoptosis by angularly resolved light scattering and cryoimaging," Proc. SPIE 6087, 60870K (2006).

[22] L. Z. Li, "Imaging mitochondrial redox potential and its possible link to tumor metastatic potential," J. Bioenerg. Biomembr. 44, 645-653 (2012).

[23] B. Chance, H. Baltscheffsky, "Respiratory enzymes in oxidative phosphorylation. VII. Binding of intramitochondrial reduced pyridine nucleotide," J. Biol. Chem. 233, 736-739 (1958).

[24] B. Chance, G. R. Williams, "A method for the localization of sites for oxidative phosphorylation," Nature 176, 250-254 (1955).

[25] I. J. Fidler, "Review: Biologic heterogeneity of cancer metastases," Breast Cancer Res. Treat. 9, 17-26 (1987).

[26] I. J. Fidler, I. R. Hart, "Biological diversity in metastatic neoplasms: Origins and implications," Science 217, 998-1003 (1982).

[27] G. H. Heppner, "Tumor heterogeneity," Cancer Res. 44, 2259-2265 (1984).

[28] G. H. Heppner, F. R. Miller, "The cellular basis of tumor progression," Int. Rev. Cytol. 177, 1-56 (1998).

[29] M. Gerlinger, A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, S. Begum, N. Q. McDonald, A. Butler, D. Jones, K. Raine, C. Latimer, C. R. Santos, M. Nohadani, A. C. Eklund, B. Spencer-Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P. A. Futreal, C. Swanton, "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing," N. Engl. J. Med. 366, 883-92 (2012).

[30] H. N. Xu, T. A. Mir, S. C. Lee, M. Feng, N. Farhad, R. Choe, J. D. Glickson, L. Z. Li, "Mapping the Redox State of CHOP-treated Non-Hodgkin's Lymphoma Xenografts in Mice," Adv. Exp. Med. Biol. (in press.)